Semax (30 mg) is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH), specifically ACTH(4–7) (Met-Glu-His-Phe), with Pro-Gly-Pro appended at the C-terminus to enhance resistance to peptidase degradation. The compound has a molecular formula of C₃₇H₅₁N₉O₁₀S and a molecular weight of 813.9 g/mol.

In laboratory contexts, Semax is used as a neurotropic research compound, studied for its effects on brain signaling, stress-related responses, and cognitive processes. The peptide is supplied as a lyophilized powder in a 30 mg vial for flexible preparation in research protocols that require higher volumes or repeated dosing.

Semax has been explored for its role in modulating neurochemical balance and gene expression in the central nervous system, with a focus on neural pathways involved in memory, attention, and recovery.

Semax (30 mg) Key Features & Specs

• Subcategory: Brain, Cognitive & Nootropic Peptides
• Strength: 30 mg
• CAS: 80714-61-0
• Chemical Formula: C₃₇H₅₁N₉O₁₀S
• Molecular Weight: 813.9 g/mol
• Peptide Sequence: Met-Glu-His-Phe-Pro-Gly-Pro

For laboratory research use only.

Semax (30 mg) Research Uses

Semax (30 mg) is being researched as a neurobiological probe for brain function and adaptation. It is studied for its role in cognitive performance, stress response, and neural recovery, specifically how signaling molecules influence learning, attention, and behavioral flexibility.

Semax is also examined for its interactions with neurotrophic systems, including proteins such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are linked to neuronal survival and synaptic plasticity.

Additionally, Semax has been used in models of ischemic brain injury to study cellular responses related to inflammation, oxidative stress, and tissue adaptation. Its effects on immune-related signaling within the brain have also been investigated, highlighting connections between neural and immune system activity.

In human-focused research, Semax has been investigated in study cohorts involving cognitive and neurological endpoints, with outcomes evaluated alongside biochemical markers.

Semax (30 mg) Insights & Observed Findings

Preclinical studies suggest that Semax can influence gene expression patterns in the brain, particularly in areas involved in immune response and vascular regulation.

• In rodent models of cerebral ischemia, the peptide has been associated with changes in genes linked to inflammation, cell survival, and repair mechanisms. These results suggest that Semax affects multiple biological systems simultaneously under experimental conditions.
• Other studies have reported changes in protein markers like CREB, c-Fos, and matrix metalloproteinases following Semax exposure. These proteins indicate neuronal activity, stress response, and structural remodeling.
• Dosing in preclinical research has been conducted in microgram-per-kilogram ranges, particularly in rodent studies using intranasal or parenteral administration. In clinical research, dosing protocols vary, with some studies using repeated daily administration to assess neurological and cognitive outcomes.
• Behavioral studies in animals and humans have explored memory retention, attention, and stress response.

Results remain dependent on study design, dosing conditions, and population characteristics. All findings are exploratory and guide further investigation rather than confirming clinical efficacy.

Semax (30 mg) Handling & Storage

• Store as a lyophilized powder at –20°C in a sealed container.
• Protect from light and moisture to maintain peptide integrity.
• Allow the vial to reach room temperature before opening to reduce condensation.
• Reconstitute using a sterile diluent and aseptic techniques.
• After reconstitution, store at 2–8°C for short-term use.
• Follow standard laboratory handling practices to ensure reliable experimental outcomes.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15(1):228. doi:10.1186/1471-2164-15-228
2. Sudarkina OYu, Filippenkov IB, Stavchansky VV, et al. Brain protein Expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (SEMAX) in a rat model of cerebral Ischemia–Reperfusion. International Journal of Molecular Sciences. 2021;22(12):6179. doi:10.3390/ijms22126179
3. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain‐derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;97(s1):82-86. doi:10.1111/j.1471-4159.2006.03658.x